Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients with Castration-Resistant Prostate Cancer

Inclusion Criteria

• Histologically proven prostate cancer
• Known metastatic disease: on previous imaging, or PSA value >= 1 ng/ml
• Castration resistant disease with confirmed testosterone level =< 50 ng/ml under prior first-line androgen deprivation therapy (ADT)
• New planned treatment with enzalutamide or abiraterone, darolutamide or apalutamide
• Willingness to undergo ARSI throughout the duration of the study as prescribed by the treating uro-oncologist
• Stated willingness to comply with continuation of ARSI treatment for the duration of the study
• Provision of signed and dated informed consent form

Exclusion Criteria

• Inability to provide written informed consent
• Known inability to remain still and lie flat for duration of each imaging procedure (about 30 minutes)
• Other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy
• A baseline superscan pattern on bone scan
• Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, patients with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible